Table 3.

Clinical and non-invasive bioengineering assessment at baseline (D0) and after four weeks (D28), Mean ± SEM (n = 10).

Skin Parameter	Baseline	Day 28
Local SCORAD
Verum	6.3 ± 1.0	2.3 ± 0.7
Placebo	5.3 ± 1.0	4.1 ± 0.8
Itch
Verum	3.8 ± 0.5	1.6 ± 1.4
Placebo	3.9 ± 0.7	3.4 ± 0.8
Sleeplessness
Verum	2.9 ± 0.9	2.2 ± 0.8
Placebo	2.9 ± 0.9	2.5 ± 1.0
TEWL
Verum	27 ± 7	16 ± 4
Placebo	27 ± 8	25 ± 7
Skin capacitance
Verum	20 ± 5	28 ± 5
Placebo	23 ± 5	25 ± 5
Skin erythema
Verum	340 ± 30	340 ± 40
Placebo	340 ± 40	310 ± 20